Although exogenously imposed AEFs are not specifically tied to a singular signal transduction pathway in cancer cells, we have recently reported that phosphatase and tensin homolog (PTEN) mutations predict benefit from TTFields in patients with recurrent isocitrate dehydrogenase (IDH) wild-type GBM [90], which represents the first molecular biology-based predictor of responsiveness to TTFields therapy. This evidence concerns the gene PTEN and cancer.